Showing 8 of 8 recruiting trials for “primary-malignant-peritoneal-tumor”
PTC-Guided Therapy for Peritoneal Mesothelioma
A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
👨⚕️ Yongkun Sun, Doctor, Cancer Institute and Hospital, Chinese Academy of Medical SciencesCancer📍 1 site📅 Started Jan 2024View details ↗
RecruitingNCT06581549 ↗
Immune Microenvironment and Gene Expression Profiling in Mesothelioma
👨⚕️ Giulia Pasello, MD, Istituto Oncologico Veneto IOV IRCCS📍 10 sites📅 Started Nov 2023View details ↗
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
👨⚕️ Ping Chi, MD, PhD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Apr 2021View details ↗
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
👨⚕️ Angela Hirbe, M.D., Ph.D., Washington University School of Medicine📍 13 sites📅 Started Apr 2017View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →